the trial in our study was prospective, randomized, and placebo-controlled -this is the best design to minimize the selection bias between the study group and the control group. Accordingly, we suggest that the significantly lower number of patients with an NIHSS score of at least 8 in the EPO group in comparison with the placebo group could refl ect simply the therapeutic benefi t of EPO therapy in improving the 90-day neurological outcome rather than a mere speculation of a higher rate of recur rent strokes in the placebo group.
Th e optimal dosage of EPO and duration of treatment for patients after IS remain uncertain. Th is may account for some inconsistency in improvement of neurological outcome after IS in clinical trials [1] [2] [3] [4] . Accordingly, we disagree with Minnerup and colleagues [5] that 'the potential side eff ects and the failed effi cacy in large clinical trials will presumably prevent the use of EPO as a therapy to increase EPCs after stroke' .
Minnerup and colleagues also underscored that the study was fi rst assigned to a trial register (ISRCTN 96340690) in January 2011, which was 10 months after the inclusion of the last patients in March 2010 [5] . We would like to underscore that, in addition to receiving institutional review board approval, our study [1] was reviewed and approved by the National Science Council of Taiwan before implementation. Actually, our clinical trial started long before we applied for an assignment to a trial registry. We believe that well-controlled studies remain the primary bases of scientifi c progress. Further evidence is required for solid conclusions to be made. Abbreviations EPC, endothelial progenitor cell; EPO, erythropoietin; NIHSS, National Institutes of Health Stroke Scale; IS, ischemic stroke; tPA, tissue plasminogen activator.
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